stockportfolio.pro
STAAR Surgical Company (STAA)
Healthcare · Medical Instruments & Supplies · NasdaqGM
STAAR Surgical Company revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2020 | 2021 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $82.43M | $90.61M | $123.95M | $150.19M | $163.46M | $230.47M | $284.39M | $322.42M | $313.90M | $239.44M |
| Gross profit | $58.37M | $64.28M | $91.51M | $111.95M | $118.36M | $178.64M | $223.38M | $252.65M | $239.58M | $182.42M |
| Net income | $-12.13M | $-2.14M | $4.97M | $14.05M | $5.91M | $27.51M | $39.01M | $21.35M | $-20.21M | $-80.45M |
| Net margin | -14.7% | -2.4% | 4.0% | 9.4% | 3.6% | 11.9% | 13.7% | 6.6% | -6.4% | -33.6% |
Source: STAAR Surgical Company SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of STAAR Surgical Company financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track STAA in your portfolio →
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
STAAR Surgical Company — frequently asked questions
What is STAAR Surgical Company's revenue?
STAAR Surgical Company (STAA) reported revenue of $239.44M for fiscal year 2025, down 23.7% from the prior year, according to its SEC filings.
Is STAAR Surgical Company profitable?
No — STAA reported a net loss of $-80.45M in fiscal 2025.
What is STAA's P/E ratio?
STAAR Surgical Company trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is STAAR Surgical Company growing?
STAA's revenue grew at roughly 7.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from STAAR Surgical Company's official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.